From Corporate Philanthropy to Creating Shared Value: Big Pharma’s New Business Models in Developing Markets
Some big companies have discovered opportunities to bolster their bottom line in emerging and developing markets by creating social value at the same time as generating economic returns. In the pharma industry some have taken the lead in using this concept of shared value to innovate and grow their...
Main Author: | Smith N. Craig |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2016-05-01
|
Series: | GfK Marketing Intelligence Review |
Subjects: | |
Online Access: | http://www.degruyter.com/view/j/gfkmir.2016.8.issue-1/gfkmir-2016-0005/gfkmir-2016-0005.xml?format=INT |
Similar Items
-
Big Pharma, Big Business
by: Sorin-George Toma, et al.
Published: (2021-01-01) -
Words for pharma: a quantitative and qualitative analysis on vision, mission and values of multinational pharma companies.
by: Giulio Zuanetti, et al.
Published: (2020-04-01) -
Recent trends in specialty pharma business model
by: Mannching Sherry Ku
Published: (2015-12-01) -
On the Valuation of ‘Big Pharma’s’ Research Pipelines
by: Löfqvist, Martin
Published: (2009) -
The War on Drugs in Contrast to the War on Big Pharma: Contextualizing Shifts in Drug Policy During the Opioid Crisis
by: Carter, Alexandra
Published: (2019)